| , | Application No. | Applicant(s) | |
|--|---|---|------------|
| N-4 CAU 199 | 09/690,044 | LINDBERG ET AL. | |
| Notice of Allowability | Examiner | Art Unit | |
| | Celia Chang | 1625 | |
| The MAILING DATE of this communication appearing being allowable, PROSECUTION ON THE MERITS IS (ith (or previously mailed), a Notice of Allowance (PTOL-85) of CE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGORIES or upon petition by the applicant. See 37 CFR 1.313 | OR REMAINS) CLOSED in other appropriate comm GHTS. This application is and MPEP 1308. | in this application. If not included nunication will be mailed in due cou subject to withdrawal from issue at | ırse. THIS |
| This communication is responsive to <u>IDS filed 10/4/04 and I</u> | preliminary amenament da | <u>itea 07/08/04</u> . | |
| The allowed claim(s) is/are <u>1 and 43-53</u> . | | | |
| The drawings filed on are accepted by the Examiner | • | | |
| Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). Certified copies not received: | been received. been received in Applicati | on No | from the |
| licant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMING THREE-MONTH PERIOD IS NOT EXTENDABLE. | | e a reply complying with the require | ements |
| A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give | | | ICE OF |
| CORRECTED DRAWINGS (as "replacement sheets") must including changes required by the Notice of Draftspersor 1 hereto or 2 to Paper No./Mail Date including changes required by the attached Examiner's Paper No./Mail Date entifying indicia such as the application number (see 37 CFR 1.3 ch sheet. Replacement sheet(s) should be labeled as such in the | on's Patent Drawing Revie Amendment / Comment of | or in the Office action of the drawings in the front (not the bac | ck) of |
| DEPOSIT OF and/or INFORMATION about the depos attached Examiner's comment regarding REQUIREMENT F | | | the |
| nment(s) Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date Examiner's Comment Regarding Requirement for Deposit f Biological Material | 6. ☐ Interview S Paper No 8), 7. ☐ Examiner's | nformal Patent Application (PTO-19) Summary (PTO-413), ./Mail Date s Amendment/Comment s Statement of Reasons for Alloward Celia Chang Primary Examiner Art Unit 1625 | , |
| | | | |

Application/Control Number: 09/690,044

Art Unit: 1625

DETAILED ACTION

1. This application is a RCE of SN 09/690,044 filed Oct. 4, 2004.

A preliminary amendment was filed on July 8, 2004. Claims 2-42 have been canceled. Claims 1, 43-53 are pending.

A 1449 was filed on Oct. 4, 2004 which has been considered and an initialed copy is attached.

2. Reason for Allowance

The following is an examiner's statement of reasons for allowance:

Applicants have made of record an opposition proceeding before the EPO with respect to the patent family application of the instant claims. The most relevant references in the opposition proceeding are EP0124495 and DE4035455 and both references were recited on the PTO-1449 dated Oct. 16, 2000 and were considered by the examiner during prosecution. The chemical compound structures corresponding to EP0124495 (CA102:137795) and DE4035455 (CA117:90285) were carefully compared to the instant claims. The EP0124495 disclosed racemate complex of the magnesium salt of (±)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole. The DE4035455 disclosed no magnesium salt only the free base of (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole. Since the omeprazole free base is known to racemize thus does not render pure enantiomeric salt preparation using the free base obvious (see CA 114:74595). Therefore, the instant claims explicitly pointing to the single, nonracemic magnesium salt of (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole with a purity limitation is neither anticipated nor rendered obvious by the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 09/690,044

Art Unit: 1625

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang Oct. 26, 2004 Celia Chang Primary Examiner Art Unit 1625

ali Ch